Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature

M Fraenkel¹, M Kim¹*, A Faggiano²-³, W W de Herder⁴, G D Valk⁵ and On behalf of the Knowledge NETwork

Endocrinology, Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheeba, Israel
¹Mount Sinai Medical Center, New York, New York, USA
²Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy
³Endocrinology, National Cancer Institute, Fondazione G. Pascale, Naples, Italy
⁴Erasmus MC, Rotterdam, The Netherlands
⁵Department of Internal Medicine, Division of Gastroenterology, University Medical Center Utrecht, Utrecht, The Netherlands
*(M Fraenkel and M Kim contributed equally to this work)

Correspondence should be addressed to M Fraenkel
Email meravfra@gmail.com

Abstract

Based on the current medical literature, the worldwide incidence of neuroendocrine tumours (NETs) seems to have increased; however, a systematic literature overview is lacking. This study aimed to collect all available data on the incidence of gastroenteropancreatic (GEP)-NETs and characteristics of population to establish their epidemiology. A sensitive MEDLINE search was carried out. The papers were selected via a cascade process that restricted the initial pool of 7991 articles to 33, using predefined inclusion and exclusion criteria. Original articles evaluating the incidence of sporadic GEP-NETs in regional, institutional and national registries were considered. The majority of data originated from the US National Cancer Institute Surveillance, Epidemiology and End Results database and from national cancer registries in Western Europe. Generally, because of the retrospective nature of existing databases the outcomes of studies might be biased, which hinders the drawing of firm conclusions. The age-adjusted incidence of GEP-NETs has increased steadily over the past four decades (1973–2007), increasing 3.65-fold in the USA and 3.8- to 4.8-fold in the UK. Incidence has changed variably from one anatomical site to another. The greatest increase in incidence occurred for gastric and rectal NETs, while the smallest increase occurred for small intestine NETs. There were gender and racial differences, which differed site by site and, in some cases, changed over time. The incidence rates (IRs) of GEP-NETs have increased significantly in the last 40 years. Data are only available from North America, Western Europe and Japan. A site-by-site analysis revealed that the IRs of some NETs increased more than those of others.

Key Words
- neuroendocrine tumours
- carcinoids
- epidemiology
- incidence

Introduction

Neuroendocrine tumours (NETs) are heterogeneous neoplasms arising from different cells distributed in many organs and tissues that share a common neuroendocrine phenotype. NETs have been recognized as biologically different from classical carcinomas since the first description of a ‘karzinoid’ by Oberndorfer at the
beginning of the twentieth century (Oberndorfer 1907). However, only in recent years have well-defined histo-
logical and immunohistochemical criteria allowed clin-
icians to reliably identify NETs and differentiate them
from other types of tumours. The World Health Orga-
nization (WHO) classification criteria of NETs, which
have been revised recently by an international pathological
board, are basic instruments that have superseded all
previous NET classifications and terms, such as APUDoma,
argentaffinoma and carcinoid (Klimstra et al. 2010a,b,
Kloppel et al. 2010).

The most recent 2010 WHO system renders all NETs
as neoplasms with a malignant potential and the
 acronym NEN is recommended corresponding to the
term neuroendocrine neoplasia (Klimstra et al. 2010a,b,
Kloppel 2011).

Nowadays, more and more NETs are being diagnosed
in surgical samples or biopsy, in the absence of a classical
clinical picture suggestive of NETs. Furthermore, highly
sensitive and specific imaging techniques, such as com-
puted tomography (CT), SPECT with 111In-pentetreotide
and positron emission tomography with 68Ga-DOTA-
TATE, 11C 5-HTP and 18F-DOPA, multidetector-row CT,
endoscopic ultrasound and video capsule endoscopy, are
now available to help detect and localize symptomatic and
asymptomatic NETs (Kwekkeboom et al. 2009, Sundin
et al. 2009).

Despite several recent articles from monocentric and
multicentric national studies being published, we still lack
adequate epidemiological information on NETs. This lack
of data only partially explains the strong discrepancy
between the estimated incidence of gastroenteropancre-
tic (GEP)-NETs and the higher frequency of these tumours
found in autopsy series (Berge & Linell 1976).

The aim of this study was to carry out a systematic
literature review to collect all available data on the
worldwide epidemiology, and specifically incidence, of
GEP-NETs and to identify potential trends in the incidence
rates (IRs) of these tumours.

Materials and methods

Prospective and retrospective epidemiological studies that
evaluated the incidence and/or prevalence of GEP-NETs in
people at any age were considered. Studies were included
if they reported the incidence and/or prevalence of
GEP-NETs. Autopsy series were excluded. Only original
articles were included; review articles and abstracts were
excluded. Studies on patients with multiple endocrine
neoplasia (MEN1) and other familial NETs were excluded.

A search strategy that included search terms on study
design, patient group, clinical problem and outcome of
interest was implemented using the MEDLINE database
(1966–07/2011). Search terms were ‘Incidence’(Mesh)
OR ‘Data Collection’(Mesh) OR ‘Prevalence’(Mesh))
AND ((‘Neuroendocrine Tumors’(Mesh) OR ‘Carcinoma,
Neuroendocrine’(Mesh) OR ‘Gastro-enteropancreatic
neuroendocrine tumor’ (Supplementary Concept))
OR ((neuroendocrine AND (tumors OR tumour)) OR
(neuro-endocrine AND (tumors OR tumour)) OR (neuro
dermocrine AND (tumors OR tumour)) OR (neuroendocrine
carcinoma) OR (neuro-endocrine carcinoma) OR (neuro
dermocrine carcinoma) OR (gastro entero pancreatic
neuroendocrine tumors) OR (GEP neuroendocrine
tumor) OR (gastro entero pancreatic NETs) OR (GEP
NETs) OR (gip tumor) OR (gip tumour) OR (gip net) OR
(gip neuroendocrine tumor) OR (gip NETs) OR carcinoid*
OR insulinoma* OR gastrinoma*.

There were no language restrictions. Studies reporting
on regional, institutional and national registries were
included if they reported annual IRs. The bibliographies of
all the retrieved and relevant publications identified by the
search were investigated for further relevant studies. All
the identified references were assessed by title and abstract
to determine possible eligibility; i.e. whether these met the
inclusion criteria: concerning patient group: patients with
GEP-NETs and outcomes reported: incidence and/or
prevalence and type of registry (i.e. national, regional or
institutional). Full-paper copies of the subsequent ident-
ified articles were retrieved, and each was assessed for
eligibility using pre-defined data extraction sheets. Studies
were excluded if they reported IRs of all NETs with no
specific data on GEP-NETs separately. Each paper included
was further assessed and information was extracted using
standard data extraction sheets. Data on the country or
region, type of registry, patient identification procedure,
patient population (location of primary tumour and type
of tumour), reported time period and outcomes (incidence
and/or prevalence figures) were collected. In case of doubt,
the papers were discussed in teams of at least two reviewers
and a consensus was reached.

Particularly in the USA where the Surveillance,
Epidemiology and End Results (SEER) database is publicly
available, different groups had used the same data and
reported similar IRs over similar time periods. In the
majority of cases, we included all papers as the studies
reported the incidence of NETs using different inclusion
criteria or reported it in different ways (e.g. annually vs
5-year incidence). When the same group published
updated data in the same way, the reports were grouped
together. Extracted data are summarized in evidence tables on a study-by-study narrative basis (for full data tables, see the Supplementary appendix, see section on supplementary data given at the end of this article). Because of the heterogeneity of study design, registry type, follow-up and outcomes, no attempt was made to pool the results. The evidence tables were compiled following collective discussion by the working party. IRs were reported as the number of cases per 100 000 persons in the population studied per year (unless otherwise stated). In cases where age-adjusted IRs were reported, these values were used.

Results

Of the 7991 publications that came up in the initial search, 199 papers were judged to be potentially eligible based on their title and abstract and were reassessed on a full-text basis. A total of 33 papers fulfilled all the specified inclusion and exclusion criteria. These publications covered the IRs of GEP-NETs at different time periods between the years 1958 and 2007 in different parts of the world (Fig. 1). None of the reports included data on the prevalence of GEP-NETs by anatomical location in the gastrointestinal (GI) tract. Yao et al. (2008) reported an estimated 29-year limited-duration prevalence of NETs on 1 January 2004 in the USA of 103 312 cases or 35/100 000. Reports on the IRs of GEP-NETs were mainly from North America and Western Europe with one report being from Japan (also reporting prevalence rates) (Fig. 1). The majority of data from North America originated from the US SEER database. Incidence was usually reported as annual age-adjusted incidence per 100 000 population. In some cases, incidence was reported separately for males and females and by race; in others, incidence was reported for the whole population without separating the genders or race.

The methods of patient identification for national and regional registries included in this review are listed in Table 1.

Data from the USA

Numerous cancer registries exist in the USA on national, state and institutional levels. The majority of, and most robust, epidemiological studies have been carried out using the national registries. The End Results Group included cancer cases from 1950 to 1969. The Third National Cancer Survey was a more short-lived registry including patients from 1969 to 1971. More recently, the most prominent studies have been carried out using the SEER cancer registry. The most up-to-date SEER data represent ~28% of the population of the USA and includes information on 7 262 696 cancer patients diagnosed from 1973 to 2009. The SEER database is considered...
to be roughly representative of the US population with respect to features such as socio-economic status, education, and urban/rural residence (seer.cancer.gov website).

Data from outside the USA

In Europe, data on the incidence of GEP-NETs, separated by anatomical location, arise from the national and regional registries. The countries in Europe for which IRs were reported specifically for GEP-NETs (fulfilling our inclusion criteria) were the UK, Sweden, Norway, France, Switzerland, Austria and Italy. In some of the countries, IRs were published several times for different time periods, allowing some insights into trends in the incidence of GEP-NETs (the UK, France, Switzerland, Norway and Sweden). Some countries reported large series of GEP-NET patients but were not population based and therefore could not report on annual IRs (Li et al., 2008, Younes 2008, Lombard-Bohas et al., 2009, Ploeckinger et al., 2009, Garcia-Carbonero et al., 2010). Some registries reported the IRs of all GEP-NETs or all NETs, including lung NETs, and not site-specific IRs (Scotland, The Netherlands, Denmark and early reports from England and Ireland), and were therefore not included in this review (Buchanan et al., 1986, Watson et al., 1989, Newton et al., 1994, Westergaard et al., 1995, Quaedvlieg et al., 2001). There was only one study conducted outside of the USA and Europe that qualified for this review, originating in Japan (Ito et al., 2010).

Overall GEP-NET incidence

Although several registries published data on the IRs of all-site NETs, they were not included in this review as they published data on those of tumours of non-GEP sites (mainly lung) and were not solely dedicated to GEP-NETs.

In the USA, the incidence of GEP-NETs has increased steadily over the past four decades. In the most recent epidemiological study, 29,664 patients with GEP-NETs were identified from the SEER database from 1973 to 2007. Between 1973 and 1977, the age-adjusted IR for all GEP-NETs was 1.00, increasing to 3.65 between 2003 and 2007 (Lawrence et al., 2011). In the UK, the IR of GI-NETs (excluding pancreatic NETs) increased by 4.8 times in males and 3.8 times in females from the 1970s to the years between 2000 and 2006 (from 0.27 to 1.32 in males

<table>
<thead>
<tr>
<th>Country</th>
<th>Method of patient identification for national/regional registry</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>USA (SEER database)a</td>
<td>Various editions of the ICD-O codes</td>
<td>Chow et al. (1996), Severson et al. (1996), Modlin &amp; Sandor (1997), Crocetti &amp; Paci (2003), Modlin et al. (2003, 2007), Maggard et al. (2004), Hodgson et al. (2005), Yao et al. (2007, 2008), Gustafsson et al. (2008), Halfdanarson et al. (2008), Hauso et al. (2008), Bilimoria et al. (2009), and Lawrence et al. (2011)</td>
</tr>
<tr>
<td>Norway</td>
<td>Physicians and pathology departments reporting to national registry with check by the Norwegian registry of cancer</td>
<td>Hauso et al. (2008)</td>
</tr>
<tr>
<td>UK</td>
<td>Regional registries based on ICD-O codes</td>
<td>Ellis et al. (2010)</td>
</tr>
<tr>
<td>Switzerland (Vaud)</td>
<td>Voluntary agreement between recording medical institutions and the registry. Unclear how patients are identified</td>
<td>Levi et al. (1993, 2000)</td>
</tr>
<tr>
<td>Sweden</td>
<td>National registry based on the ICD-7 codes</td>
<td>Hemminki &amp; Li (2001) and Landerholm et al. (2010)</td>
</tr>
<tr>
<td>Italy (Tuscany)</td>
<td>Regional cancer registry based on the ICD-O codes</td>
<td>Crocetti et al. (1997) and Caldarella et al. (2011)</td>
</tr>
<tr>
<td>Austria</td>
<td>Registry based on reports from 40 of the 41 pathology departments</td>
<td>Niederle et al. (2010)</td>
</tr>
<tr>
<td>France (Burgundy)</td>
<td>Data collected by cancer registry staff using multiple databases: pathology laboratories, university hospitals, local hospitals, private surgeons, oncologists, gastroenterologists, general practitioners, and monthly reviews of death certificates</td>
<td>Lepage et al. (2004, 2006)</td>
</tr>
<tr>
<td>Japan</td>
<td>Questionnaire to heads of departments about the number of patients with GEP-NET</td>
<td>Ito et al. (2010)</td>
</tr>
</tbody>
</table>


aSurveillance, Epidemiology and End Results.
and from 0.35 to 1.33 in females) (Ellis et al. 2010). The absolute rate of GEP-NETs in the UK was significantly lower than that in the USA over similar time periods. While possibly being explained by true variations in incidence, influenced by local genetic and environmental conditions, these discrepancies mainly raise major concerns on the validity of the method of patient identification used in the different registries and in the same registry over time.

### Gastric NETs

The IRs of gastric NETs are particularly difficult to assess as registries do not differentiate among type I, II and III gastric NETs. Moreover, the registration of these tumours in different cancer registries is variable, with some only documenting malignant tumours while others documenting benign and malignant tumours. In the SEER database up to 1986, only malignant gastric NETs were registered. The differentiation between benign and malignant gastric NETs is not acceptable any more, as all types have various grades of malignant potential (Klimstra et al. 2010a).

In the 1970s, incidence was low: 0.01 in both the USA and the UK (Maggard et al. 2004, Ellis et al. 2010; for details, see Supplementary appendix Table 1, see section on supplementary data given at the end of this article).

Most recently, the highest IRs of gastric NETs have been reported in the USA (Lawrence et al. 2011) and somewhat lower IRs in Norway (Hauso et al. 2008), the UK (Ellis et al. 2010) and Austria (Niederle et al. 2010; Fig. 2A).

There has been an increase in IRs over time in the USA, Switzerland and Norway (Levi et al. 2000, Hauso et al. 2008, Yao et al. 2008, Ellis et al. 2010, Lawrence et al. 2011). The most dramatic increases were reported in the UK (15-fold) and in the USA (11-fold) (Modlin & Sandor 1997, Maggard et al. 1997, 2003, 2004, Maggard et al. 2004, Hodgson et al. 2005, Yao et al. 2008, Ellis et al. 2010, Lawrence et al. 2011). It remains unclear whether this represents a true increase in incidence or reflects increased awareness, changes in method of registration (‘malignant’ vs ‘benign’ and ‘malignant’ tumours) and mainly the increase in the availability and usage of upper endoscopy.

In the USA, there was initially a suggestion that female gender could be protective (Modlin et al. 2004); however, this no longer holds true, as the IRs of gastric NETs now tend to be similar in males and females (Yao et al. 2008). In the USA, over the past 30 years, gastric carcinoids have consistently been more common in Blacks than in Whites (Modlin & Sandor 1997, Modlin et al. 1997, 2003, 2004, Crocetti & Paci 2003, Lawrence et al. 2011).

### Small intestine-NETs

In older classification systems, duodenal tumours were classified as foregut carcinoids. In most recent classifications, NETs of the duodenum are considered a distinct entity (Klimstra et al. 2010a, Klöppel 2011).

Despite this, many of the reports summarized in this review included tumours of the duodenum with and without those of the jejunum/ileum as a group of small intestine-NETs (SI-NETs), while others included those arising in all the three sites together.

SI-NETs have been the most common GEP-NETs in the Western world for many years (Ellis et al. 2010, Lawrence et al. 2011), and only recently have they been surpassed by rectal NETs in the USA (Lawrence et al. 2011).

In the 1970s, the lowest IR was recorded in the UK (0.11–0.12) (Ellis et al. 2010). During the same period, IRs in the USA were higher, ranging from 0.28 to 0.82 (lowest in White females and highest in Black males) (Godwin 1975, Maggard et al. 2004, Gustafsson et al. 2008; for details, see Supplementary appendix Table 2, see section on supplementary data given at the end of this article).

Data from different time periods indicate a clear increase in the IRs of SI-NETs over time. Between 1971 and 2006, the increase in IR in the UK was ~3.8-fold in men and 2.9-fold in women (Ellis et al. 2010), and in the latest report from the SEER database, a 2.8-fold increase has been demonstrated comparing the IR recorded in the early 1970s with that recorded in the mid-2000s (Billimoria et al. 2009, Lawrence et al. 2011). Smaller increases with different trends in males and females were observed in Sweden (Hemminki & Li 2001, Landerholm et al. 2010), Burgundy, France (Lepage et al. 2004), Vaud, Switzerland (Levi et al. 2000), and Norway (Hauso et al. 2008). While the increase in the IRs of ‘incidental’ tumours due to increased imaging and awareness can explain the increase in those of other GEP-NETs, this is less relevant to SI-NETs, which are usually not amenable to luminal imaging with endoscopic techniques.

In recent years, significantly higher IRs have been recorded (Fig. 2B). The highest IR of SI-NETs has been recorded in the USA with similarly high IRs being reported over similar time frames in Norway and Jonkoping County, Sweden (Hauso et al. 2008, Landerholm et al. 2010, Lawrence et al. 2011). Lower IRs have been recorded in the latest reports from the UK (Ellis et al. 2010) and Austria (Niederle et al. 2010; see Fig. 2B).

Of note is that this more than twofold variation in the IR of SI-NETs in the USA compared with that in the UK and some other western European countries (see Fig. 2B) raises...
The highest IR was reported in the USA and the lowest in Austria

Increase in IR over time in all countries reporting data

16- and 15-fold increase in males and females respectively in the UK between 1971 and 2006

The highest IR was reported in the USA and the lowest in France and Austria

Increase in IR over time in all countries reporting data

Little data on IR of pancreatic NETs in Europe

In general, IRs reported in the USA seemed to be higher than those reported in Europe

Within the colon, there was a predominance of right-sided NETs

Over time, there has been an increase in the IR in the UK, the USA and Norway

The highest IRs were reported in Sweden and the UK and the lowest in Austria

Difficult to ascertain patterns due to different coding of appendiceal NETs over time and across the countries

The highest IRs were reported in Sweden and the USA and the lowest in Austria

Within the colon, there was a predominance of right-sided NETs

Over time, there has been an increase in the IR in the UK, the USA and Norway

Figure 2
Most recent incidence rates in various countries for six types of NET: (A) gastric, (B) small intestine, (C) pancreatic, (D) colon, (E) rectal, and (F) appendiceal NETs. Data for the various countries are from the following time periods: USA, 2003–2007 (Lawrence et al. 2011); UK, 2000–2006 (Ellis et al. 2010); Austria, 2004–2005 (Niederle et al. 2010); Italy (Tuscany), 1985–2005 (Caldarella et al. 2011); Norway, 2000–2004 (Hauso et al. 2008); Switzerland (Vaud), 1986–1997 (Levi et al. 2000); Sweden, 1983–1998 (Hemminki & Li 2001); France (Burgundy), 1989–2001 (Lepage et al. 2006).
some major concerns as to the validity of the various registries and reflects the variation in the methods of patient identification in each country.

In the US SEER registry, jejunal/ileal NETs were the most common among SI-NETs (Yao et al. 2008, Lawrence et al. 2011), and they are more common in African Americans than in Whites (for details, see Supplementary appendix Table 2; Godwin 1975, Chow et al. 1996, Severson et al. 1996, Modlin & Sandor 1997, Modlin et al. 2003, Yao et al. 2008, Modlin et al. 2004). Male predominance has been reported in most of the countries reporting the IRs of SI-NETs.

Pancreatic NETs

The most recently reported IRs of pancreatic NETs are shown in Fig. 2C (and in more detail in Supplementary appendix Table 3, see section on supplementary data given at the end of this article).

In Europe, few reports on the incidence of pancreatic NETs fulfilled our selection criteria. In the USA, the IR of pancreatic NETs has increased with time as apparent from several reports (Modlin et al. 2003, Halldanarson et al. 2008, Hauso et al. 2008), with the most recent one showing an increase from 0.17 in 1973–1977 to 0.43 in 2003–2007 (Lawrence et al. 2011). Surprisingly, there were major differences in IRs in the different reports based on the SEER database, which may be explained by differences in the ICD code selection. For example, Yao et al. (2007), specifically evaluating the IR of islet cell carcinoma, found a decrease in IR with time between 1973 and 2003. In Norway, the IR of pancreatic NETs doubled from 0.15 to 0.3 between the mid-1990s and the early 2000s (Hauso et al. 2008).

In general, IRs in the USA seem to be slightly higher than those in Europe, with a male predominance in France, the USA and Norway, but a female predominance in Italy. In the US SEER population, pancreatic NETs were more common in Whites and African Americans (0.32 and 0.36 respectively) than in Asian Americans and American Indians (0.25 and 0.20 respectively) (Yao et al. 2008).

Colorectal NETs

The incidence of NETs of the colorectum was difficult to assess, as registries variably reported the IRs of colorectal, colon and rectal NETs either together or separately. In addition, some reports included appendiceal NETs (ANETs) with colorectal NETs. Comparisons between geographical areas were especially challenging because of these differences in classification. The incidence of colorectal NETs has increased over the last 40 years. It remains unclear whether this reflects a true increase in incidence or increased availability and usage of flexible sigmoidoscopy and colonoscopy.

Colon NETs

The most recently reported IRs of colon NETs are shown in Fig. 2D (for more details, see Supplementary appendix Table 4, see section on supplementary data given at the end of this article). Generally, there was predominance of right-sided NETs in the colon (Ballantyne et al. 1992, Crocetti & Paci 2003, Modlin et al. 2003, Yao et al. 2008, Ellis et al. 2010, Lawrence et al. 2011).

In the 1970s, the IRs of colon NETs in the UK were as low as 0.05 (Ellis et al. 2010). From the 1970s to the mid-2000s, IRs increased approximately fourfold in the UK and more than doubled in the US SEER population (Modlin & Sandor 1997, Modlin et al. 2003, Maggard et al. 2004, Gustafsson et al. 2008, Hauso et al. 2008, Ellis et al. 2010, Lawrence et al. 2011). Smaller increases in IR have been observed in Norway (Hauso et al. 2008). Interestingly, a recent report from Austria has demonstrated a particularly low IR of 0.06 for colon NETs in the mid-2000s (Niederle et al. 2010).

Racial and gender differences in IRs have also been demonstrated. The IRs of colon NETs remained highest in African Americans (0.38), with lower IRs being observed in American Indians (0.22) and Whites (0.18) and the lowest IR in Asians (0.12) (Yao et al. 2008). With respect to gender, the IRs of colon NETs were higher in males in the USA (Godwin 1975, Hauso et al. 2008, Yao et al. 2008), but the opposite was true in Italy, Norway and Sweden (Hemminki & Li 2001, Hauso et al. 2008, Caldarella et al. 2011).

Rectal NETs

The most recently reported IRs of rectal NETs are shown in Fig. 2E (for more details, see Supplementary appendix Table 5, see section on supplementary data given at the end of this article). In the early 1970s, the IRs for rectal NETs were ten times lower in the UK than in the USA (0.01 and 0.1 per 100 000 respectively) (Godwin 1975, Modlin & Sandor 1997, Modlin et al. 2003, Ellis et al. 2010, Lawrence et al. 2011). From the 1970s to the mid-2000s, IRs increased approximately tenfold in both the countries, reaching a maximum of only 0.12 in the UK when compared with 1.05 in the US SEER population (Ellis et al. 2010, Lawrence et al. 2011). The lowest IR of rectal NETs has been reported in Austria, which was 0.03 in the mid-2000s (Niederle et al. 2010). Modest increases in the IRs of rectal NET have been reported from other European countries such as Norway (Hauso et al. 2008).
Racial and gender differences in the incidence of rectal NETs have been reported. In the USA, racial differences in the incidence of rectal NETs have been demonstrated, with the highest frequency in African Americans (1.80), followed by that in Asian Americans (1.25) and American Indians (1.0), and the lowest frequency in Whites (0.66) (Godwin 1975, Modlin & Sandor 1997, Modlin et al. 2003, Yao et al. 2008). In the UK and Norway, the IRs of rectal NETs were only slightly higher in males than in females, and there were no gender differences in Italy and Sweden (Hemminki & Li 2001, Hauso et al. 2008, Ellis et al. 2010, Caldarella et al. 2011).

Appendiceal NETs

The most recently reported IRs of ANETs are shown in Fig. 2F (for more details, see Supplementary appendix Table 6, see section on supplementary data given at the end of this article).

The registration of ANETs has changed over time, depending on whether only malignant tumours or both benign and malignant tumours were included.

In the 1970s, the lowest IRs were recorded in the UK and were 0.03 in males and 0.05 in females (21, Ellis). During the same period, IRs in the USA were slightly higher at 0.07–0.12 (Godwin 1975, Modlin & Sandor 1997, Modlin et al. 2003, Maggard et al. 2004, Gustafsson et al. 2008, Lawrence et al. 2011).

The IR of ANETs has increased over time in all the countries. Interpreting this increase in IR is complex due to the differences in registration mentioned earlier (Hemmminki & Li 2001, Ellis et al. 2010, Caldarella et al. 2011). Another source of error in reporting the incidence of ANETs is the fact that it is often an incidental finding, and removed appendices are sent for pathology with a frequency that may vary between countries and over time.

The most dramatic increase in IR was observed in the UK (tenfold) between 1979 and 2006, largely explained by the change in the International Classification of Disease for Oncology (ICD-O) coding, which from 1995 onwards included both benign and malignant ANETs (Ellis et al. 2010). In Norway and the USA, IRs increased much more mildly (about twofold) over various time periods (Hauso et al. 2008, Lawrence et al. 2011).

In recent years, significantly higher IRs have been recorded: highest in the UK (Ellis et al. 2010) and significantly lower over similar time frames in the USA (Yao et al. 2008, Lawrence et al. 2011), Norway (Hauso et al. 2008) and Austria (Niederle et al. 2010; see Fig. 2F).

The IRs of ANETs are higher in females than in males in all countries reporting incidence by gender, and as of the 1990s, ANETs are the most common GI-NETs in women in the UK (Ellis et al. 2010). In the US SEER registry, the IRs of ANETs are several fold higher in Whites and African Americans than in Asian Americans and American Indians (see Supplementary appendix Table 6; Yao et al. 2008).

Data from Japan

The study carried out by Ito et al. (see Supplementary appendix Table 7, see section on supplementary data given at the end of this article), reporting on the incidence of GEP-NETs in Japan, is unique in several aspects. It is one of the few reporting on the prevalence as opposed to just incidence. The calculation of IRs was not done by identifying patients according to the ICD-O codes in cancer registries. Rather, a nationwide survey of GEP-NET patients in Japan who received treatment from 1 January to 31 December 2005 was conducted in a sample of hospitals and departments that were chosen using stratified random sampling. This study differs from all other studies included in this review, in that it used the old classification of NETs: foregut, midgut and hindgut. For these reasons, it is difficult to make comparisons between IRs from Japan and other parts of the world (Ito et al. 2010).

Discussion

By reviewing all the published articles concerning the epidemiology of GEP-NETs, we found that 33 were population-based studies providing information on the incidence of these tumours per year. Our findings are briefly summarized below.

Data source

The IRs of GEP-NETs are available from national and regional cancer registries in North America, Western Europe and Japan, but not from other parts of the world.

Most of the published data on the epidemiology of NETs are based on small and heterogeneous series, where the real incidence of these tumours for most sites is not completely known and probably not reliably estimated. In this review, we included only publications that strictly fulfilled our inclusion criteria to present only true IRs, at the national or regional level. Table 1 presents the heterogeneity of data sources and means of registration.
used by the different studies included in this review and thus explains why pooling of data in the form of a meta-analysis was not possible. This may also explain part of the differences observed in the IRs of GEP-NETs between the USA and Europe, which to our opinion cannot be completely attributed to a true variation in IRs.

Major changes have been made in the classification of NETs from their original identification by Oberndorfer in the early 1900s, who coined the term ‘karzinoid’ (Oberndorfer 1907). Inconsistency in the nomenclature and classification of NETs is the major limitation to the elucidation of the precise epidemiology of GEP-NETs. This is reflected in the ICD-O coding system that used one of several names to describe the same tumour: apudoma/carcinoid tumour/enterochromaffin cell carcinoid and so on (Lawrence et al. 2011). Another source of error as to the true incidence of GEP-NETs is that older cancer registries included only ‘malignant carcinoids’ while not including ‘benign’ tumours. At the same time, other registries reported both ‘benign’ and ‘malignant’ tumours. This has changed, with the new ICD-O 10 coding already including ‘benign’ NETs, and may explain some of the increase in the incidence of GEP-NETs being reported around the world. Furthermore, the current NET classification (WHO and ENETS) does not discriminate between benign and malignant NETs; rather, the classification relies on histological grade and differentiation, rendering all NETs as neoplasms with a degree of malignant potential (Klöppel et al. 2009, Klimstra et al. 2010a,b).

**Trends in IRs**

The age-adjusted incidence of all GEP-NETs has steadily increased in the last four decades, increasing in the time interval 1973–2007 by 3.6-fold in the USA and by 3.8- to 4.8-fold in Europe. The small intestine (SI) and rectum are currently the most common primary sites for GEP-NETs.

The highest increase in IR in recent years/decades has been observed for gastric and rectal NETs, whereas the IRs of SI-NETs have changed least among the various sites/locations.

There are gender and racial differences, which differ site by site and, in some cases, change over time and are different between countries and continents.

**Limitations of the available data**

Our findings were limited by the heterogeneity of data reporting and presentation and by the fact that some of the reports were not population based and therefore did not report annual IRs, with very little data on prevalence rates. Heterogeneity was apparent in several aspects including different countries and study populations; different methods of patient identification (see Table 1); different time intervals during which incidence data were calculated; variations in the way data were presented (age, gender and race); site of origin of the tumour; and grade of malignancy. Only one study used the 2000 WHO classification (Austria), and no studies used the 2010 WHO classification. Most reports had a retrospective study design with only one prospective study (Austria) in which IRs were established taking into account all diagnoses of NETs made in that country in 1 year. Multiple reports for the same population, e.g. the numerous SEER-based publications, were not always consistent with each other. As of the second decade of the twenty-first century, data on the IRs of GEP-NETs are still lacking in many parts of the world, including the Far East and Africa.

The assessment of trends in the IRs of GEP-NETs is confounded by multiple factors. The classification of GEP-NETs has changed with time. Benign tumours were not included in some of the older studies, while today we know that all NETs have a malignant potential. In addition, the increased awareness of NETs in clinicians and pathologists and the use of NET classifications in more recent years might at least partly explain the increase in the incidence of NETs being reported. Both awareness of NETs by clinicians and pathologists and increase in the clinical use of luminal and anatomical imaging have probably contributed significantly to the increase in the IRs of GEP-NETs being reported, while the precise contribution of the true increase is hard to assess. It is our opinion, based on the existing data, that it is impossible to draw conclusions as to the true trends in the IRs of GEP-NETs around the world.

**The future**

Future studies in the field of GEP-NET epidemiology should aim to report annual age-adjusted IRs and prevalence rates. Population-based studies, ideally of whole countries, identifying all NET cases on the basis of standardized collection of pathology reports, using a uniform classification system, preferably based on the most updated WHO classification, should be carried out to assess the possible topographical differences and changes in incidence with time. These studies should be conducted in different parts of the world. Overall, this information may promote our understanding of the genetic and
environmental factors that contribute to the development of GEP-NETs in different parts of the world.

Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.1530/ERC-13-0125.

Declaration of interest
M F, M K, A F and G D V have no conflicts of interest to declare. W D H has been on advisory boards organized by Novartis and Ipsen.

Funding
This article was developed independently by members of a working group of the Knowledge Network. This programme involved meetings and collaboration between clinicians working in the field of NETs around the world, which was organized and funded by Ipsen. The authors are fully responsible for the concept and all the content, for all the editorial decisions, and for the approval of the final version.

Author contribution statement
All authors screened the search results and compiled datasets with IRRs of the study population and wrote the manuscript and reviewed the final version.

Acknowledgements
The authors thank the participants of the Knowledge Network. They also thank Alex Coulthard of Echo Communications, UK, for editorial assistance, funded by Ipsen, in the preparation of this manuscript.

References
Published by Bioscientifica Ltd.

http://erc.endocrinology-journals.org
DOI: 10.1530/ERC-13-0125
© 2014 Society for Endocrinology
Printed in Great Britain

Downloaded from Bioscientifica.com at 03/15/2019 07:39:10 PM
via free access
Review

Epidemiology of GEP-NETs

21:3

R163

M Fraenkel, M Kim et al.


Received in final form 6 December 2013
Accepted 9 December 2013
Made available online as an Accepted Preprint
9 December 2013